• ANKIT SONI Department of Pharmaceutics, Seth G. L. Bihani S. D. College of Technical Education, Gagan Path, Sri Ganganagar, Rajasthan, India.
  • MAHESH KUMAR KATARIA Department of Pharmaceutics, Seth G. L. Bihani S. D. College of Technical Education, Gagan Path, Sri Ganganagar, Rajasthan, India.



In situ gel , Gastroesophageal reflux disease, omeprazole magnesium, Polymers, In vitro floating duration, In vitro gelling capacity bioavailability


Objective: Omeprazole magnesium is indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease. It is one of the highly prescribed proton pump inhibitor in the management of peptic ulcer diseases. The therapeutic concentration of a drug in blood can be maintained for a prolonged period of time by administering it in the form of in situ floating gel dosage form. Omeprazole magnesium undergoes degradation at a low pH of the esophagus and stomach; it is therefore given as in situ gel, so, there is minimum contact with acidic pH.

Methods: Omeprazole magnesium suspension prepared using various polymers and floating agents in varying concentrations. Several evaluation tests including dissolution test to ensure the release of the drug from formulation by in vitro technique, color and homogeneity, in vitro floating duration, in vitro gelling capacity, drug content determination, pH of the formulation, and floating lag time were studied.

Results: All formulations demonstrated good Fourier-transform infrared compliance and no interaction between drug, polymer, and other excipients. The study’s findings show that the formulation F6 showed the best results.

Conclusion: The developed formulation was a viable alternative conventional solution by virtue of its ability to enhance bioavailability through its longer gastric residence time and ability to sustain drug release as well as the advantage of floating and pH which minimize the degradation of omeprazole magnesium which is easily degraded by acidic environment.


Download data is not yet available.


Li S, Mirchandani HL, Chien TW. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev Ind Pharm 2012;28:783-93.

Darekar AB, Patil VA, Gondkar SB. Development and characterization of novel in-situ floating gel of levocetirizine dihydrochloride for oral drug delivery system. Der Pharm Lett 2016;8:188-96.

Devault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2015;100:190-200.

Available from: Omeprazole-magnesium.

Kumar R, Singh H, Singh P. Development of UV Spectrophotometric method for estimation of pantoprazole in pharmaceutical dosage forms. J Chem Pharm Res 2017;3:113-7.

Edith B. Development and Examination of Solubility Measurement Methods for Drug Solubility Determination. Hungary: Semmelweis University, Department of Pharmaceutical Chemistry, Budapest; 2010.

Maharjan R, Subedi G. Formulation and evaluation of floating in situ gel of ranitidine using natural polymers. Int J Pharm Pharm Sci 2014;6:205-9.

Chauhan B, Shimpi S, Mahadik A. Preparation and evaluation of floating risedronate sodium gelucire matrices. Acta Pharm Sin B J 2014;54:205-21.

Basu S, Bandyopadhyay A. Development and characterization of mucoadhesive in situ nasal gel of midazolam prepared with Ficus carica mucilage. Am Assoc Pharm Sci PharmSciTech 2017;3:1223-31.

Desai S, Bolton S. A floating controlled release drug delivery system: In vitro-in vivo evaluation. Pharm Res 1992;10:1321-5.

Frances S, John T. A review on in situ floating gel of telmesartan. Int J Pharm 2008;3:301-11.

Suvakanta D. Kinetic modeling on drug release from controlled drug delivery systems. Actapoloniaepharm Drug Res 2010;67:217-23.

Thomas LM. Formulation and evaluation of floating oral in-situ gel of metronidazole. Int J Pharm Pharm Sci 2014;6:205-9.



How to Cite

SONI, A., and MAHESH KUMAR KATARIA. “FORMULATION AND EVALUATION OF FLOATING IN SITU GEL OF OMEPRAZOLE MAGNESIUM FOR ORAL DRUG DELIVERY SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, vol. 14, no. 9, Sept. 2021, pp. 44-52, doi:10.22159/ajpcr.2021.v14i9.42231.



Original Article(s)